Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer

NMR in Biomedicine

Volumn 25, Issue 9, 2012, Pages 1033-1042

  Cao, Maria D ^a,b   Döpkens, Mailin ^a,c   Krishnamachary, Balaji ^a   Vesuna, Farhad ^a   Gadiya, Mayur M ^a   Lønning, Per E ^d,e   Bhujwalla, Zaver M ^a   Gribbestad, Ingrid S ^b   Glunde, Kristine ^a,f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c UNIVERSITY OF BREMEN   (Germany)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF BERGEN   (Norway)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Breast cancer; Choline kinase; Choline phospholipid metabolism; Glycerophosphodiester phosphodiesterase domain containing 5; MRS

Indexed keywords

BREAST CANCER; CHOLINE KINASE; CHOLINE PHOSPHOLIPID METABOLISM; MRS; PHOSPHODIESTERASES;

BIOMOLECULES; CELL CULTURE; CELLS; DEGRADATION; ENZYMES; ESTERS; GENE ENCODING; GLYCEROL; METABOLISM; METABOLITES; PHOSPHOLIPIDS; PHYSIOLOGY; TRANSCRIPTION; TUMORS;

DISEASES;

CHOLINE DERIVATIVE; CHOLINE KINASE; ESTROGEN RECEPTOR; GLYCEROPHOSPHODIESTER PHOSPHODIESTERASE DOMAIN CONTAINING 5; GLYCEROPHOSPHORYLCHOLINE; ISOENZYME; PHOSPHODIESTERASE; PHOSPHOLIPASE D1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER PATIENT; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID METABOLISM; METABOLITE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; BREAST NEOPLASMS; CELL EXTRACTS; CELL LINE, TUMOR; CHOLINE; CHOLINE KINASE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METABOLOME; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PHOSPHOLIPASE D; PHOSPHOLIPIDS; PHOSPHORIC DIESTER HYDROLASES; RNA, MESSENGER;

EID: 84861425810     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.2766     Document Type: Article

References (51)

1. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Research 2004; 64: 4270-4276.
2. Glunde K, Bhujwalla ZM. Metabolic tumor imaging using magnetic resonance spectroscopy. Seminars in Oncology 2011; 38: 26-41.
3. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. Journal of the National Cancer Institute 2002; 94: 1197-1203.
4. Meisamy S, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, Nelson MT, Emory TH, Tuttle TM, Yee D, Garwood M. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy-a pilot study at 4 T. Radiology, 2004; 233: 424-431.
5. Glunde K, Jacobs MA, Bhujwalla ZM. Choline metabolism in cancer: implications for diagnosis and therapy. Expert Review of Molecular Diagnostics 2006; 6: 821-829.
6. Manton DJ, Chaturvedi A, Hubbard A, Lind MJ, Lowry M, Maraveyas A, Pickles MD, Tozer DJ, Turnbull LW. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. British Journal of Cancer, 2006; 94: 427-435.
7. Baek HM, Chen JH, Nalcioglu O, Su MY. Proton MR spectroscopy for monitoring early treatment response of breast cancer to neo-adjuvant chemotherapy. Annals of Oncology 2008; 19: 1022-1024.
8. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Research 1999; 59: 80-84.
9. Hernandez-Alcoceba R, Fernandez F, Lacal JC. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Research 1999; 59: 3112-3118.
10. Rodriguez-Gonzalez A, Ramirez de Molina A, Fernandez F, Ramos MA, del Carmen Nunez M, Campos J, Lacal JC. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene 2003; 22: 8803-8812.
11. Glunde K, Raman V, Mori N, Bhujwalla ZM. RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Research. 2005; 65: 11 034-11 043.
12. Krishnamachary B, Glunde K, Wildes F, Mori N, Takagi T, Raman V, Bhujwalla ZM. Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft. Cancer Research 2009; 69: 3464-3471.
13. Foster DA, Xu L. Phospholipase D in cell proliferation and cancer. Molecular Cancer Research 2003; 1: 789-800.
14. Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, Podo F. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Research 2005; 65: 9369-9376.
15. Iorio E, Ricci A, Bagnoli M, Pisanu ME, Castellano G, Di Vito M, Venturini E, Glunde K, Bhujwalla ZM, Mezzanzanica D, Canevari S, Podo F. Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Research 2010; 70: 2126-2135.
16. Katz-Brull R, Degani H. Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Research 1996; 16: 1375-1380.
17. Katz-Brull R, Seger D, Rivenson-Segal D, Rushkin E, Degani H. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Research 2002; 62: 1966-1970.
18. Eliyahu G, Kreizman T, Degani H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. International Journal of Cancer, 2007; 120: 1721-1730.
19. Nakagami K, Uchida T, Ohwada S, Koibuchi Y, Morishita Y. Increased choline kinase activity in 1, 2-dimethylhydrazine-induced rat colon cancer. Japanese Journal of Cancer Research 1999; 90: 1212-1217.
20. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez-Pineiro L, Sanchez J, Bonilla F, Rosell R, Lacal J. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochemical and Biophysical Research Communications. 2002; 296: 580-583.
21. Ramirez de Molina A, Banez-Coronel M, Gutierrez R, Rodriguez-Gonzalez A, Olmeda D, Megias D, Lacal JC. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Research. 2004; 64: 6732-6739.
22. Ramirez de Molina A, Gutierrez R, Ramos MA, Silva JM, Silva J, Bonilla F, Sanchez JJ, Lacal JC. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene, 2002; 21: 4317-4322.
23. Al-Saffar NM, Troy H, Ramirez de Molina A, Jackson LE, Madhu B, Griffiths JR, Leach MO, Workman P, Lacal JC, Judson IR, Chung YL. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Research 2006; 66: 427-434.
24. 1H HR-MAS and genomic analysis of human tumor biopsies discriminate between high and low grade astrocytomas. NMR in Biomedicine 2009; 22: 629-637.
25. 1H high resolution magic angle spinning (HRMAS) NMR spectroscopy. Journal of Proteome Research 2010; 9: 319-332.
26. 1H HR-MAS total correlation spectroscopy. Magnetic Resonance in Medicine 2008; 60: 33-40.
27. Kwon ED, Zablocki K, Jung KY, Peters EM, Garcia-Perez A, Burg MB. Osmoregulation of GPC:choline phosphodiesterase in MDCK cells: different effects of urea and NaCl. American Journal of Physiology 1995; 269: C35-C41.
28. Zablocki K, Miller SP, Garcia-Perez A, Burg MB. Accumulation of glycerophosphocholine (GPC) by renal cells: osmotic regulation of GPC:choline phosphodiesterase. Proc. Natl. Acad. Sci. USA, 1991; 88: 7820-7824.
29. Rao M, Sockanathan S. Transmembrane protein GDE2 induces motor neuron differentiation in vivo. Science, 2005; 309: 2212-2215.
30. Periz G, Yan Y, Bitzer ZT, Sockanathan S. GDP-bound Galphai2 regulates spinal motor neuron differentiation through interaction with GDE2. Developmental Biology 2010; 341: 213-221.
31. Nogusa Y, Fujioka Y, Komatsu R, Kato N, Yanaka N. Isolation and characterization of two serpentine membrane proteins containing glycerophosphodiester phosphodiesterase, GDE2 and GDE6. Gene, 2004; 337: 173-179.
32. Lang Q, Zhang H, Li J, Yin H, Zhang Y, Tang W, Wan B, Yu L. Cloning and characterization of a human GDPD domain-containing protein GDPD5. Molecular Biology Reports 2008; 35: 351-359.
33. Gallazzini M, Ferraris JD, Burg MB. GDPD5 is a glycerophosphocholine phosphodiesterase that osmotically regulates the osmoprotective organic osmolyte GPC. Proc. Natl. Acad. Sci. USA, 2008; 105: 11 026-11 031.
34. Wu M, Ji C, Xu J, Zou X, Wang L, Zheng H, Jin F, Wang Y, Gu S, Ying K, Xie Y, Mao Y. A novel splice variant of human gene GDPD1 is mainly expressed in human ovary and small intestine. International Journal of Molecular Medicine 2003; 12: 1003-1007.
35. Chang PA, Shao HB, Long DX, Sun Q, Wu YJ. Isolation, characterization and molecular 3D model of human GDE4, a novel membrane protein containing glycerophosphodiester phosphodiesterase domain. Molecular Membrane Biology 2008; 25: 557-566.
36. Yanaka N, Imai Y, Kawai E, Akatsuka H, Wakimoto K, Nogusa Y, Kato N, Chiba H, Kotani E, Omori K, Sakurai N. Novel membrane protein containing glycerophosphodiester phosphodiesterase motif is transiently expressed during osteoblast differentiation. Journal of Biological Chemistry. 2003; 278: 43 595-43 602.
37. Corda D, Kudo T, Zizza P, Iurisci C, Kawai E, Kato N, Yanaka N, Mariggio S. The developmentally regulated osteoblast phosphodiesterase GDE3 is glycerophosphoinositol-specific and modulates cell growth. Journal of Biological Chemistry. 2009; 284: 24 848-24 856.
38. Glunde K, Guggino SE, Solaiyappan M, Pathak AP, Ichikawa Y, Bhujwalla ZM. Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia, 2003; 5: 533-545.
39. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 2001; 25: 402-408.
40. Chrisanthar R, Knappskog S, Lokkevik E, Anker G, Ostenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, Lonning PE. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One, 2008; 3: e3062.
41. Mangia A, Chiriatti A, Chiarappa P, Incalza MA, Antonaci G, Pilato B, Simone G, Tommasi S, Paradiso A. Touch imprint cytology in tumor tissue banks for the confirmation of neoplastic cellularity and for DNA extraction. Archives of Pathology & Laboratory Medicine 2008; 132: 974-978.
42. Sitter B, Bathen T, Tessem M, Gribbestad I. High-resolution magic angle spinning (HR MAS) MR spectroscopy in metabolic characterization of human cancer. Progress in Nuclear Magnetic Resonance Spectroscopy 2009; 54: 239-254.
43. Sitter B, Bathen TF, Singstad TE, Fjosne HE, Lundgren S, Halgunset J, Gribbestad IS. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR in Biomedicine 2010; 23: 424-431.
44. Desbiens NA. A novel use for the word 'trend' in the clinical trial literature. The American Journal of the Medical Sciences 2003; 326: 61-65.
45. Sakagami H, Aoki J, Natori Y, Nishikawa K, Kakehi Y, Arai H. Biochemical and molecular characterization of a novel choline-specific glycerophosphodiester phosphodiesterase belonging to the nucleotide pyrophosphatase/phosphodiesterase family. Journal of Biological Chemistry. 2005; 280: 23 084-23 093.
46. Gozgit JM, Pentecost BT, Marconi SA, Ricketts-Loriaux RS, Otis CN, Arcaro KF. PLD1 is overexpressed in an ER-negative MCF-7 cell line variant and a subset of phospho-Akt-negative breast carcinomas. British Journal of Cancer, 2007; 97: 809-817.
47. Osborne CK. Tamoxifen in the treatment of breast cancer. The New England Journal of Medicine 1998; 339: 1609-1618.
48. Hackshaw A, Roughton M, Forsyth S, Monson K, Reczko K, Sainsbury R, Baum M. Long-term benefits of 5years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50years of age with early breast cancer. Journal of Clinical Oncology 2011; 29: 1657-1663.
49. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature, 2001; 410: 37-40.
50. Ramirez de Molina A, Penalva V, Lucas L, Lacal JC. Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K. Oncogene, 2002; 21: 937-946.
51. Pai JK, Frank EA, Blood C, Chu M. Novel ketoepoxides block phospholipase D activation and tumor cell invasion. Anti-Cancer Drug Design 1994; 9: 363-372.